Effects of substitution on the pyrrole N atom in derivatives of tetrahydronaltrindole, tetrahydrooxymorphindole, and a related 4,5-epoxyphenylpyrrolomorphinan

Journal of Medicinal Chemistry

Volumn 47, Issue 26, 2004, Pages 6645-6648

  Srivastava, Sanjay K ^a   Shefali, ^a   Miller, Carl N ^b   Aceto, Mario D ^c   Traynor, John R ^b   Lewis, John W ^a   Husbands, Stephen M ^a  

^a University of Bath   (United Kingdom)

^b UNIVERSITY OF MICHIGAN   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 CYCLOPROPYLMETHYL 3,14 DIHYDROXY 4,5 EPOXY 4' PHENYL 6,7:2',3' PYRROLOMORPHINAN; 4,5 EPOXYPHENYLPYRROLOMORPHINAN; DELTA OPIATE RECEPTOR; DELTA OPIATE RECEPTOR AGONIST; DELTA OPIATE RECEPTOR ANTAGONIST; INDOLE DERIVATIVE; N METHYL N [7 (1 PYRROLIDINYL) 1 OXASPIRO[4.5]DEC 8 YL]BENZENEACETAMIDE; NALTRINDOLE; OPIATE; OXYMORPHINDOLE; TETRAHYDRONALTRINDOLE; TETRAHYDROOXYMORPHINDOLE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BINDING ASSAY; CHO CELL; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG BINDING; DRUG EFFICACY; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; MICHAEL ADDITION; RECEPTOR BINDING; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

ANALGESICS; ANIMALS; BINDING, COMPETITIVE; CHO CELLS; CRICETINAE; CRICETULUS; HUMANS; INDOLES; LIGANDS; MORPHINANS; NALTREXONE; RADIOLIGAND ASSAY; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 10644224324     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm040817t     Document Type: Article

References (21)

1. Dondio, G.; Ronzoni, S.; Petrillo, P. Non-peptide δ opioid agonists and antagonists. Expert Opin. Ther. Pat. 1997, 7, 1075-1098.
2. Dondio, G.; Ronzoni, S.; Petrillo, P. Non-peptide δ opioid agonists and antagonists (Part II). Expert Opin. Ther. Pat. 1999, 9, 353-374.
3. Schmidhammer, H. Opioid receptor antagonists. Progress in Medicinal Chemistry; Ellis, G. P., Luscombe, D. K., Oxford, A. W., Eds.; Elsevier Science: Amsterdam, 1998; Vol. 35, pp 83-132.
4. McLamore, S.; Ullrich, T.; Rothman, R. B.; Xu, H.; Dersch, C.; Coop, A.; Davis, P.; Porreca, F.; Jacobson, A. E.; Rice, K. C. Effect of N-alkyl and N-alkenyl substituents in noroxymorphindole, 17-substituted-6,7-dehydro-4, 5α-epoxy-3,14-dihydroxy-6,7:2′,3′-indolomorphinans, on opioid receptor affinity, selectivity and efficacy. J. Med. Chem. 2001, 44, 1471-1474.
5. Schutz, J.; Dersch, C. M.; Horel, R.; Spetea, M.; Koch, M.; Meditz, R.; Greiner, E.; Rothman, R. B.; Schmidhammer, H. Synthesis and biological evaluation of 14-alkoxymorphinans. 17. Highly δ opioid receptor selective 14-alkoxy-substituted indolo- and benzofuromorphinans. J. Med. Chem. 2002, 45, 5378-5383.
6. Stevens, W. C.; Jones, R. M.; Subramanian, G.; Metzger, T. G.; Ferguson, D. M.; Portoghese, P. S. Potent and selective indolomorphinan antagonists of the κ-opioid receptor. J. Med. Chem. 2000, 43, 2759-2769.
7. Portoghese, P. S.; Sultana, M.; Takemori, A. E. Design of peptidomimetic δ opioid receptor antagonists using the message-address concept. J. Med. Chem. 1990, 33, 1714-1720.
8. Clayson, J.; Jales, A.; Tyacke, R. J.; Hudson, A. L.; Nutt, D. J.; Lewis, J. W.; Husbands, S. M. Selective δ-opioid receptor ligands: Potential PET ligands based on naltrindole. Bioorg. Med. Chem. Lett. 2001, 11, 939-943.
9. Korlipara, V. L.; Takemori, A. E.; Portoghese, P. S. N-Benzylnaltrindoles as long-acting δ opioid receptor antagonists. J. Med. Chem. 1994, 37, 1882-1885.
10. Lever, J. R.; Johnson, S. Synthesis of tritiated N1′-alkyl derivatives of the delta opioid receptor ligand naltrindole. J. Labeled Compd. Radiopharm. 1987, 39, 115-122.
11. Srivastava, S. K.; Husbands, S. M.; Aceto, M. D.; Miller, C. N.; Traynor, J. R.; Lewis, J. W. 4′-Arylpyrrolomorphinans: Effect of a pyrrolo-N-benzyl substituent in enhancing δ-opioid antagonist activity. J. Med. Chem. 2002, 45, 537-540.
12. Portoghese, P. S.; Nagase, H.; MaloneyHuss, K. E.; Lin, C.-E.; Takemori, A. E. Role of spacer and address components in peptidomimetic üopioid receptor antagonists related to naltrindole. J. Med. Chem. 1991, 34, 1715-1720.
13. Toll, L.; Berzetei-Gurske, I. P.; Polgar, W. E.; Brandt, S. R.; Adapa, I. D.; Rodriguez, L.; Schwartz, R. W.; Haggart, D.; O'Brian, A.; White, A. Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications. NIDA Res. Monogr. 1998, 178, 440-466.
14. Pearl, J.; Harris, L. S. Inhibition of writhing by narcotic antagonists. J. Pharmacol. Exp. Ther. 1986, 154, 319-323.
15. Broom, D. C.; Jutkiewicz, E. M.; Folk, J. E.; Traynor, J. R.; Rice, K. C.; Woods, J. H. Convulsant activity of a non-peptidic δ-opioid receptor agonist is not required for its antidepressant-like effects in Sprague-Dawley rats. Psychopharmacology 2002, 164, 42-48.
16. Farouz-Grant, F.; Portoghese, P. S. Pyrrolomorphinans as δ opioid receptor antagonists. The role of steric hindrance in conferring selectivity. J. Med. Chem. 1997, 40, 1977-1981.
17. Casy, A. F.; Parfitt, R. T. Opioid Analgesics: Chemistry and Receptors; Plenum Press: New York, 1986; p 518.
18. Husbands, S. M.; Lewis, J. W. Structural determinants of efficacy for κ opioid receptors in the orvinol series: 7,7-spiro analogues of buprenorphine. J. Med. Chem. 2000, 43, 139-141.
19. Chauvignac, C.; Traynor, J. R.; Lewis, J. W.; Husbands, S. M. Investigations towards ligands having MOR agonist and KOR antagonist activity. Presented at the European Opioid Conference, 2004; Visegrad, Hungary.
20. Ananthan, S.; Kezar, H. S., III; Carter, R. L.; Saini, S. K.; Rice, K. C.; Wells, J. L.; Davis, P.; Xu, H.; Dersch, C. M.; Bilsky, E. J.; Porreca, F.; Rothman, R. B. Synthesis, opioid receptor binding and biological activities of naltrexone-derived pyrido- and pyrimidomorphinans. J. Med. Chem. 1999, 42, 3527-3538.
21. Iijima, I.; Minamikawa, J.-I.; Jacobson, A. E.; Brossi, A.; Rice, K. C. Studies in the (+)-morphinan series. 5. Synthesis and biological properties of (+)-naloxone. J. Med. Chem. 1978, 21, 398-400.